Abstract | BACKGROUND:
XP-828L, a protein extract obtained from sweet whey, has demonstrated potential benefit for the treatment of mild to moderate psoriasis in an open-label study. OBJECTIVE: To study in a randomized, double-blind, placebo-controlled study the safety and efficacy of XP-828L in the treatment of mild to moderate psoriasis. DESIGN:
XP-828L 5 g/d (group A, n = 42) or placebo (group B, n = 42) was given orally for 56 days followed by XP-828L 5 g/d in group A and by XP-828L 10 g/d in group B for an additional 56 days. RESULTS: Patients receiving XP-828L 5 g/d for 56 days had an improved Physician's Global Assessment ( PGA) score compared with patients under placebo (p < .05). Considering the data of group A only, the PGA score improved from day 1 to day 56 (p < .01); the Psoriasis Area and Severity Index score improved as well, but to a lesser extent (p < .05). CONCLUSION:
|
Authors | Yves Poulin, Robert Bissonnette, Christina Juneau, Kim Cantin, Rejean Drouin, Patrice E Poubelle |
Journal | Journal of cutaneous medicine and surgery
(J Cutan Med Surg)
2006 Sep-Oct
Vol. 10
Issue 5
Pg. 241-8
ISSN: 1203-4754 [Print] United States |
PMID | 17234108
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Dermatologic Agents
- Milk Proteins
- Placebos
- XP-828l
|
Topics |
- Administration, Oral
- Adult
- Analysis of Variance
- Chi-Square Distribution
- Dermatologic Agents
(administration & dosage, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Milk Proteins
(administration & dosage, therapeutic use)
- Placebos
- Psoriasis
(drug therapy)
- Severity of Illness Index
- Treatment Outcome
|